24 May 2013
Keywords: merck, co, suspends, enrollment, trial, lead, aurora
Article | 26 November 2007
USA-based drug major Merck & Co has suspended enrollment in clinical trials of its lead investigational Aurora kinase inhibitor MK-0457
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
26 November 2007
23 May 2013
© 2013 thepharmaletter.com